RONOMA
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

RONOMA Trademark

Serial Number: 79373992 • Registration: 7602065

RONOMA is a trademark filed by COMMUNAUTE UNIVERSITES ET ETABLISSEMENTS NORMANDIE UNIVERSITE on May 26, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

Trademark Details

Filing Date

May 26, 2023

Registration Date

December 17, 2024

Published for Opposition

October 15, 2024

Goods & Services

Pharmaceutical products for treating diseases of the central nervous system and neurodegenerative diseases and particularly Alzheimer's; pharmaceuticals sold on prescription, namely those treating diseases of the central nervous system and neurodegenerative diseases and particularly Alzheimer's; chemical preparations for pharmaceutical or medical use, namely for diseases of the central nervous system and neurodegenerative diseases and particularly Alzheimer's; pharmaceutical preparations against neurodegenerative diseases and diseases of the central nervous system; pharmaceutical preparations for combating the symptoms of Alzheimer's disease; Pharmaceutical preparations for the treatment of Alzheimer's disease; Pharmaceutical preparations for all means of administration, namely pharmaceutical preparations for the treatment of diseases of the central nervous system and neurodegenerative diseases and particularly Alzheimer's; pharmaceutical solutions, gels and powders for all types of administration for the treatment of diseases of the central nervous system and neurodegenerative diseases and particularly Alzheimer's; pharmaceutical preparations for treating diseases of the central nervous system and neurodegenerative diseases and particularly Alzheimer's by intranasal administration; pharmaceutical solutions, gels and powders for treating diseases of the central nervous system and neurodegenerative diseases and particularly Alzheimer's by intranasal administration

Medical research; biological research; scientific research for medical purposes in the field of diseases of the central nervous system and neurodegenerative diseases and particularly Alzheimer's; information with respect to medical and scientific research relating to diseases of the central nervous system and neurodegenerative diseases and particularly Alzheimer's; providing laboratory research services in the field of diseases of the central nervous system and neurodegenerative diseases and particularly Alzheimer's; scientific research and development for medical purposes; scientific research in the field of chemistry; scientific research in the field of pharmacology; research and development of medicines; scientific research in the field of galenics; preclinical studies and research; clinical studies and research; consultancy with respect to pharmacology

Public relations; database management; establishing statistics in the nature of compilation of statistics for business or commercial purposes; sales promotions; organization of exhibitions for commercial and advertising purposes; organizing, managing, conducting exhibitions, fairs for advertising or commercial purposes; collection and systematization of data for business purposes in a central file in the field of pharmaceutical, health and medical research and development; retail store services or wholesale store services featuring pharmaceuticals products, pharmaceutical preparations against neurodegenerative diseases and diseases of the central nervous system, pharmaceutical preparations for combating symptoms of Alzheimer's disease, pharmaceutical preparations for treating Alzheimer's disease, pharmaceutical solutions, gels and powders for all types of administration

Medical services; medical services relating to diseases of the central nervous system and neurodegenerative diseases and particularly Alzheimer's; treating symptoms relating to central nervous system diseases and neurodegenerative diseases, namely, health care services for treating symptoms relating to central nervous diseases and neurodegenerative diseases; treating diseases of the central nervous system and neurodegenerative diseases, namely, health care services for treating diseases of the central nervous system and neurodegenerative diseases; treating Alzheimer's disease and its symptoms, namely, health care services for treating Alzheimer's disease and its symptoms; medical information services; providing medical information; providing information in the field of diagnosing and treating diseases of the central nervous system and neurodegenerative diseases and particularly Alzheimer's, via a website

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Jul 5, 2025 FINO
GENERIC MADRID TRANSACTION SENT TO IB
May 23, 2025 XXSS
GENERIC MADRID TRANSACTION CREATED
May 23, 2025 XXCR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Mar 17, 2025 FICR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jan 4, 2025 OPNX
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Dec 17, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Dec 17, 2024 R.PR
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 15, 2024 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Dec 12, 2024 OPNR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 15, 2024 NPUB
PUBLISHED FOR OPPOSITION
Oct 15, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 25, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 7, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 5, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 5, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 5, 2024 TROA
REFUSAL PROCESSED BY IB
Apr 8, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 15, 2024 RFCS
REFUSAL PROCESSED BY MPU
Mar 14, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Feb 23, 2024 RFCR
NON-FINAL ACTION WRITTEN
Feb 22, 2024 CNRT
ASSIGNED TO EXAMINER
Feb 20, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Jul 18, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 14, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 13, 2023 REPR